Neurocrine biosciences announces completion of enrollment in phase 3 kinect-hd study evaluating valbenazine for chorea in huntington disease

San diego, aug. 5, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), in collaboration with the huntington study group, today announced the completion of patient enrollment for its phase 3 (kinect-hd) clinical study evaluating the efficacy, safety and tolerability of valbenazine, a selective, orally active vesicular monoamine transporter 2 (vmat2) inhibitor being investigated as a once-daily treatment in adults with chorea in huntington disease. a top-line data readout of the clinical study results is anticipated by the end of 2021.
NBIX Ratings Summary
NBIX Quant Ranking